En español
NIDA

Heroin

Gene Variants Reduce Opioid Risks

Two recent studies suggest that genotyping may enable clinicians to base therapies on individual patients’ potential responsiveness to opioid drugs’ therapeutic effects and vulnerability to their harmful effects.

Knowing When to Say When: Transitioning Patients from Opioid Therapy

Summary

Uses a case study to teach when and how to taper and/or transition patients off opioid-based medications in primary care settings

Resource Materials

Details

Naloxone—A Potential Lifesaver

Combating the epidemic of opioid abuse—including prescription painkillers and, increasingly, heroin—requires a multi-pronged approach that involves reducing drug diversion, expanding delivery of existing treatments (including medication-assisted treatments), and development of new medications for pain that can augment our existing treatment arsenal. But another crucial component we must not forget is that people who abuse or are addicted to opioids need to be kept alive long enough that they can be treated successfully. In this, the drug naloxone has a large potential role to play.

Another Reminder of the Terrible Toll of Addiction

Philip Seymour HoffmanEverett Collection / Shutterstock.com

This past weekend Americans were shocked and saddened to learn that one of our greatest actors, Philip Seymour Hoffman, had died at age 46 of an apparent heroin overdose. Hoffman’s death, in the prime of his life and career, is a poignant reminder of some of the harsh realities of a disease that 17.7 million Americans struggle with and that all too often cuts their lives short.

Abuse of Prescription Pain Medications Risks Heroin Use

1 in 15 people who take non medical prescription pain relievers will try heroin within 10 years.
English

Naltrexone Implant Outperforms Daily Pill in Russian Trial

More than half of heroin-addicted patients treated with naltrexone via an implanted delivery device maintained abstinence throughout a 6-month clinical trial in Saint Petersburg, Russia. The implant device, which releases a steady dose of naltrexone continuously for 2 months, averted relapse to heroin use three times as effectively as daily oral doses of the medication.

Dr. Marilyn Huestis Q & A: Matching Drug Effects to Drug Concentrations

Dr. Marilyn Huestis of NIDA’s Intramural Research Program talks about conducting research on drug effects with human subjects, developing tests to help law enforcement identify drugged drivers, and an assay to help identify children whose prenatal exposure to anti-HIV drugs may put them at risk for adverse developmental outcomes.

Pages